We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
- Authors
Malhotra, Binu; Moon, James; Kucuk, Omar; Clark, Joseph I.; Urba, Susan G.; Wolf, Gregory T.; Worden, Francis P.
- Abstract
Background A phase I study and an institutional pilot study in patients with metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) utilizing biweekly gemcitabine and paclitaxel (GEMTAX), showed an overall response rate of 53%. 1 This phase II trial was conducted to determine the feasibility, tolerability, and efficacy of this combination. Methods Patients with metastatic/recurrent SCCHN were treated with gemcitabine (3000 mg/m2) and paclitaxel (150 mg/m2) on days 1 and 15 of every 28-day cycle. Results In 57 patients with measurable disease, median progression-free survival (PFS) was 4 months and median overall survival (OS) was 8 months. Overall response rate of 28% and disease stabilization in 19% were seen. There were no treatment-related deaths with grade 3/4 hematologic toxicity seen in 20% of the patients. Conclusion Biweekly GEMTAX is feasible, well tolerated, and demonstrated reasonable efficacy. This may be an alternative for patients who are not candidates for platinum-based chemotherapy. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1712-1717, 2014
- Subjects
PACLITAXEL; CANCER relapse; SQUAMOUS cell carcinoma; HEAD &; neck cancer
- Publication
Head & Neck, 2014, Vol 36, Issue 12, p1712
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.23522